Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients.

Authors

• Shah, Vallari¹
• Sherborne, Amy L¹
• Johnson, David C¹
• Ellis, Sidra¹
• Price, Amy¹
• Chowdhury, Farzana¹
• Kendall, Jack¹
• Jenner, Matthew W²
• Drayson, Mark T³
• Owen, Roger G⁴
• Gregory, Walter M⁵
• Morgan, Gareth J⁶
• Davies, Faith E⁶
• Cook, Gordon⁷
• Cairns, David A⁵
• Houlston, Richard S^{1, 8}
• Jackson, Graham⁹
• Kaiser, Martin F¹⁰

• ¹ Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
• ² Department of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
• ³ Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
• ⁴ Haematological Malignancy Diagnostic Service, St. James's University Hospital, Leeds, UK. , (Mali)
• ⁵ Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds, UK.
• ⁶ Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
• ⁷ Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
• ⁸ Molecular and Population Genetics, The Institute of Cancer Research, London, UK.
• ⁹ Department of Haematology, University of Newcastle, Newcastle Upon Tyne, UK.
• ¹⁰ Division of Molecular Pathology, The Institute of Cancer Research, London, UK. [email protected]

Type

Published Article

Journal

Leukemia

Publisher

Springer Nature

Publication Date

Nov 01, 2020

Volume

34

Issue

11

Pages

3091–3096

Identifiers

DOI: 10.1038/s41375-020-0750-z

PMID: 32157174

Source

Medline

Language

English

License

Unknown